Palbociclib overcomes afatinib resistance in non-small cell lung cancer

This publication has 32 references indexed in Scilit:

• Palbociclib for the Treatment of Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer
  Clinical Cancer Research, 2015
• Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
  The Lancet Oncology, 2015
• Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis
  Journal of Clinical Oncology, 2015
• Cyclin-Dependent Kinase Inhibitors and the Treatment of Gastrointestinal Cancers
  The American Journal of Pathology, 2015
• Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations
  Critical Reviews in Oncology/Hematology, 2015
• The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
  The Lancet Oncology, 2015
• Challenges in the Management of EGFR-Mutated Non-Small Cell Lung Cancer Patients with Acquired Resistance to Tyrosine Kinase Inhibitors
  Oncology, 2014
• Afatinib in NSCLC harbouring EGFR mutations
  The Lancet Oncology, 2014
• Afatinib: A Review of Its Use in the Treatment of Advanced Non-Small Cell Lung Cancer
  Drugs, 2014
• Cyclin-dependent kinase inhibitor therapy for hematologic malignancies
  Expert Opinion on Investigational Drugs, 2013